Savient Pharma Soars on FDA Approval For Gout Treatment



Gout Uric Acid Crystals



From the Wall Street Journal and Reuters: Savient Pharmaceuticals

Wikinvest: (SVNT) Google Finance (SVNT)

Savient shares rally as FDA approves gout drug
Sept 15
Wed Sep 15, 2010 9:15am EDT

The approval is also expected to trigger a renewed interest in the company that has been looking for a strategic deal, and some analysts expect a deal within three to four months.

Savient Soars On Gout Treatment Approval While Arena Slumps On Weight Loss

Image via Wikipedia

Market Pulse
Sept. 15, 2010, 1:14 p.m. EDTSavient shares soar on FDA gout treatment approval

SAN FRANCISCO (MarketWatch) -- Shares of Savient Pharmaceuticals Inc. (SVNT 20.23, +0.25, +1.24%) jumped Wednesday after the biotech company said the Food and Drug Administration approved its gout treatment. Savient shares rose 29% to $19.09 in recent trading. The FDA approved Savient's Krystexxa for the treatment of hard-to-treat gout in adults. Gout is a type of arthritis where uric acid crystallizes in the joints causing inflammation and pain. Savient expects Krystexxa to be available on the U.S. market later in the year, and said the drug is protected by patents out to 2026

Biotech Stocks

Sept. 14, 2010, 1:11 p.m. EDT

Arena plunges on FDA news; drug indexes climb